Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?

• R. Sawaya,
• G. Saab,
• H. Moussa

Affiliations

R. Sawaya

Corresponding author.; Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon

G. Saab

Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon

H. Moussa

Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon